2739 related articles for article (PubMed ID: 15843284)
41. Hematopoietic colony-stimulating factors. Uses in combination with standard chemotherapeutic regimens and in support of dose intensification.
Neidhart JA
Cancer; 1992 Aug; 70(4 Suppl):913-20. PubMed ID: 1379115
[TBL] [Abstract][Full Text] [Related]
42. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
Ho P; Sherman P; Grigg A
Eur J Haematol; 2012 May; 88(5):416-21. PubMed ID: 22296221
[TBL] [Abstract][Full Text] [Related]
43. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
[TBL] [Abstract][Full Text] [Related]
44. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
[TBL] [Abstract][Full Text] [Related]
45. Impact of neutropenia on delivering planned chemotherapy for solid tumours.
Khan S; Dhadda A; Fyfe D; Sundar S
Eur J Cancer Care (Engl); 2008 Jan; 17(1):19-25. PubMed ID: 18181887
[TBL] [Abstract][Full Text] [Related]
46. Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte-colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor (GM-CSF).
Akasheh M; Eastwood D; Vesole DH
Bone Marrow Transplant; 2003 Jan; 31(2):113-6. PubMed ID: 12621492
[TBL] [Abstract][Full Text] [Related]
47. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
48. Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).
Holdsworth MT; Roon R; Ferguson J; Martinez L; Stidley CA; Neidhart JA
Biotechnol Ther; 1993; 4(3-4):183-95. PubMed ID: 8292969
[TBL] [Abstract][Full Text] [Related]
49. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
[TBL] [Abstract][Full Text] [Related]
50. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
51. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
Heuser M; Ganser A; Bokemeyer C; ; ;
Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
[TBL] [Abstract][Full Text] [Related]
52. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.
Peters BG; Adkins DR; Harrison BR; Velasquez WS; Dunphy FR; Petruska PJ; Bowers CE; Niemeyer R; McIntyre W; Vrahnos D; Auberry SE; Spitzer G
Bone Marrow Transplant; 1996 Jul; 18(1):93-102. PubMed ID: 8832001
[TBL] [Abstract][Full Text] [Related]
53. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey.
Repetto L;
Crit Rev Oncol Hematol; 2009 Nov; 72(2):170-9. PubMed ID: 19406660
[TBL] [Abstract][Full Text] [Related]
54. [The efficacy of G-CSF and GM-CSF in the adjunctive treatment of infections complicating chemotherapy of acute leukemia in children].
Rokicka-Milewska R; Pawelec K; Bogusławska-Jaworska J; Chybicka A; Rosińska B; Stańczak E; Matysiak M; Sońta-Jakimczyk D; Bubała H; Kołecki P; Boruczkowski D; Wysocki M; Kurylak A
Wiad Lek; 1998; 51 Suppl 4():59-64. PubMed ID: 10731945
[TBL] [Abstract][Full Text] [Related]
55. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
Johnston EM; Crawford J
Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
[TBL] [Abstract][Full Text] [Related]
56. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
Small EJ; Reese DM; Um B; Whisenant S; Dixon SC; Figg WD
Clin Cancer Res; 1999 Jul; 5(7):1738-44. PubMed ID: 10430077
[TBL] [Abstract][Full Text] [Related]
57. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.
Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Lusso MR; Camboni P; Ferreli L; Mocci M; Perboni S; Mura L; Madeddu C; Macciò A
Oncol Rep; 2003; 10(1):197-206. PubMed ID: 12469169
[TBL] [Abstract][Full Text] [Related]
58. [The hematopoietic growth factor GM-CSF in chemotherapy for advanced breast carcinoma].
Hoekman K; Wagstaff J; Boven E; van Groeningen CJ; Vermorken JB; Pinedo HM
Ned Tijdschr Geneeskd; 1991 Mar; 135(10):415-9. PubMed ID: 2020313
[TBL] [Abstract][Full Text] [Related]
59. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
Grossi F; Tiseo M
Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
[TBL] [Abstract][Full Text] [Related]
60. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
Carlson JW; Fowler JM; Saltzman AK; Carter JR; Chen MD; Mitchell SK; Dunn D; Carson LF; Adcock LL; Twiggs LB
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):415-20. PubMed ID: 7530677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]